InvestorsHub Logo

sentiment_stocks

04/06/22 2:33 AM

#457171 RE: hyperopia #457164

Great point, hyperopia! First line, here we come!…
(once we get past this damn ten yard line!)

That should tell everyone just how significant it would be for DCVax to be added as a front-line, Standard of Care for both ndGBM and rGBM. Kite is competing with Novartis and other new upcoming treatments for a second-line and third-line setting for a relatively small market. (and still able to make $1B in sales) Meanwhile, Northwest Bio is basically set to own the brain-tumor market!